<DOC>
	<DOCNO>NCT00442416</DOCNO>
	<brief_summary>This 2 arm study compare efficacy monthly Mircera epoetin alfa peritoneal dialysis patient self-inject home receive in-centre injection . The safety subcutaneous ( sc ) Mircera injection site reaction patient satisfaction also assess . Eligible patient randomize either receive monthly sc injection Mircera ( switch sc epoetin alfa ) start dose 120-360 microgram , remain standard care sc epoetin alfa . Dose adjustment permit reach/maintain hemoglobin level 10-12g/dL . The anticipated time study treatment 3-12 month , target sample size 380 individual .</brief_summary>
	<brief_title>A Study Subcutaneous Mircera Treatment Anemia Peritoneal Dialysis Patients .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic kidney disease stage V ; peritoneal dialysis 3 month prior screen ; epoetin alfa sc &gt; =3 month prior screen . patient expect change dialysis modality course study ; patient hospitalize previous 3 month clinically significant condition ; active malignancy ; bleed episode necessitate transfusion , overt gastrointestinal bleeding within 3 month prior screen ; transfusion red blood cell within 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>